Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports. A number of ...

Genomics (NASDAQ:TXG – Get Free Report) had its price target reduced by investment analysts at Citigroup from $20.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage ...

Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega ...

Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

In Monday’s trading, instrument manufacturers Pacific Biosciences and 10x Genomics each saw their stock prices dive by 13% to 14%, while industry giant Illumina—still recovering from being ...

Revenue for Q2 2024 rose to $153.1 million, up 4% year-over-year but below management's expectations. Operating expense ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...

I n a stark reflection of the challenges facing the biotech sector, 10X Genomics Inc (NASDAQ:TXG) stock has tumbled to a 52-week low, touching down at $11.89. According to InvestingPro data ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...